Q2 EPS Forecast for Monopar Therapeutics Raised by Analyst

Monopar Therapeutics Inc. (NASDAQ:MNPR) – Investment analysts at HC Wainwright upped their Q2 2026 EPS estimates for Monopar Therapeutics in a research note issued on Friday, May 15th. HC Wainwright analyst A. Maldonado now forecasts that the company will post earnings per share of ($0.68) for the quarter, up from their prior forecast of ($0.82). The consensus estimate for Monopar Therapeutics’ current full-year earnings is ($4.11) per share. HC Wainwright also issued estimates for Monopar Therapeutics’ Q3 2026 earnings at ($0.79) EPS, Q4 2026 earnings at ($0.95) EPS, FY2026 earnings at ($2.90) EPS, FY2027 earnings at ($1.37) EPS, FY2028 earnings at $0.52 EPS and FY2030 earnings at $5.50 EPS.

Monopar Therapeutics (NASDAQ:MNPR) last announced its earnings results on Thursday, May 14th. The company reported ($0.46) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.87) by $0.41.

A number of other equities analysts also recently weighed in on the stock. Cantor Fitzgerald reissued an “overweight” rating on shares of Monopar Therapeutics in a research note on Wednesday, January 21st. BTIG Research reissued a “buy” rating and set a $104.00 target price on shares of Monopar Therapeutics in a research note on Monday, February 23rd. Wall Street Zen raised shares of Monopar Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Saturday, May 9th. Weiss Ratings reissued a “sell (d-)” rating on shares of Monopar Therapeutics in a research note on Tuesday, April 21st. Finally, Chardan Capital reissued a “buy” rating and set a $100.00 target price on shares of Monopar Therapeutics in a research note on Monday, March 30th. Two research analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $107.00.

Monopar Therapeutics Stock Down 5.1%

Shares of NASDAQ MNPR opened at $56.25 on Tuesday. Monopar Therapeutics has a twelve month low of $28.40 and a twelve month high of $105.00. The firm has a fifty day simple moving average of $56.97 and a 200 day simple moving average of $65.54. The company has a market capitalization of $376.88 million, a PE ratio of -29.61 and a beta of 1.49.

Institutional Investors Weigh In On Monopar Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of MNPR. Russell Investments Group Ltd. bought a new stake in Monopar Therapeutics in the third quarter valued at $28,000. BNP Paribas Financial Markets increased its stake in Monopar Therapeutics by 100.6% in the third quarter. BNP Paribas Financial Markets now owns 696 shares of the company’s stock valued at $57,000 after purchasing an additional 349 shares in the last quarter. Meeder Asset Management Inc. bought a new stake in Monopar Therapeutics in the fourth quarter valued at $65,000. JPMorgan Chase & Co. increased its stake in Monopar Therapeutics by 1,821.0% in the second quarter. JPMorgan Chase & Co. now owns 1,921 shares of the company’s stock valued at $69,000 after purchasing an additional 1,821 shares in the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new position in shares of Monopar Therapeutics during the second quarter valued at about $80,000. 1.83% of the stock is owned by institutional investors.

About Monopar Therapeutics

Monopar Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel targeted radiotherapeutics and next-generation antibody-drug conjugates for the treatment of cancer. The company’s core technology leverages a pretargeted radioimmunotherapy (PRIT) platform designed to deliver potent radioisotopes to tumor cells while minimizing exposure to healthy tissues. By combining small-molecule binding agents with specialized radioisotopes, Monopar aims to improve the therapeutic index of radiation-based cancer therapies.

The company’s pipeline includes multiple oncology candidates in various stages of preclinical and early clinical development.